US FDA’s Record Year For Drug Approvals? Wall Street Is Unimpressed
Executive Summary
Pace of new US drug approvals is unprecedented, but investors continue to shun biopharma industry. Uncertainty about pricing environment is clearly outweighing the favorable regulatory climate. Stocks in the sector closed the year down more than 15% are still trading well below 2015 levels.
You may also be interested in...
Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment
Celgene has been vilified in the political realm for excessive price increases, which hasn’t helped its stock performance over past year and a half.
US FDA’s Best Year Ever For New Drugs: CDER Novel Approvals Hit 59
FDA’s drug center smashes its past records for new molecular entities and therapeutic biologic approvals; with five novel biologics approved by FDA’s biologics center, the agency’s novel approvals reach a stunning total of 64.
Has R&D Productivity Rebounded? US FDA Officials Think So
Record-setting pace of NME approvals is a cause for celebration. But is it a sign that drug industry R&D productivity has actually improved? The US FDA’s top drug review official thinks so – but the data aren’t yet clear.